Recommendation for risk-based bioanalytical strategy for the immunogenicity assessment for biologics

A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. 

Shankar G, Pendley C, Stein KE. Nat Biotechnol. 2007 May;25(5):555-61.

Bioanalytical assessments of anti-drug antibodies (ADAs) provide an understanding
of the immunogenicity of biological drug molecules. The potential to induce ADAs after treatment with biologics is a safety issue that has become an important consideration in the development of biologics and a critical aspect of regulatory filings. US and European regulatory agencies are recommending that sponsors study immunogenicity using a risk-based approach, encouraging sponsors to formulate and implement their own risk management plans and to conduct discussions with the agencies when necessary. It follows from this that the greater the safety risks of ADAs, the more diligently one should clarify the immunogenicity of the product. Here we propose a general strategy to broadly assign immunogenicity risk levels to biological drug products, and present risk level-based 'fit-for-purpose' bioanalytical schemes for the investigations of treatment-related ADAs in clinical and nonclinical studies.

Click here to read full text